Gain Therapeutics (GANX) vs OS Therapies (OSTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OS Therapies (OSTX) has outperformed Gain Therapeutics (GANX) over the past year, losing 20.6% versus a loss of 22.0%. OS Therapies is the larger company by market cap ($75.8 million vs $70.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | OSTX |
|---|---|---|
| Share price | $1.62 | $1.62 |
| Market cap | $70.48M | $75.82M |
| 1-day change | -3.29% | +4.52% |
| YTD return | -49.84% | +15.71% |
| 1-year return | -21.98% | -20.59% |
| 5-year return | -76.73% | — |
| Forward P/E | — | 4.67 |
| EPS (TTM) | $-0.50 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.34 | $2.25 |
| 52-week low | $1.53 | $1.15 |
| Distance from 52-week high | -62.79% | -28.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +345.82% | +424.69% |
| Average volume | 497.54K | 597.09K |
| Shares outstanding | 43.64M | 46.81M |
| Employees | 20 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Healthcare · Biotechnology · 20 employees
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Healthcare · Biotechnology · 4 employees
GANX vs OSTX FAQ
Which is bigger, Gain Therapeutics or OS Therapies?
OS Therapies (OSTX) is larger, with a market capitalization of $75.82M compared with $70.48M for Gain Therapeutics (GANX).
Which stock has performed better over the past year, GANX or OSTX?
OSTX returned -20.59% over the past 12 months, compared with -21.98% for GANX (price return, excluding dividends). Past performance does not predict future results.
Are Gain Therapeutics and OS Therapies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.